PET manufacturer Positron continues to be dogged by cash-flow problems. On July 7, the Houston-based vendor was delisted from the NASDAQ stock exchange, due to noncompliance with NASDAQ's minimum capital and surplus requirements.Financial difficulties
PET manufacturer Positron continues to be dogged by cash-flow problems. On July 7, the Houston-based vendor was delisted from the NASDAQ stock exchange, due to noncompliance with NASDAQ's minimum capital and surplus requirements.
Financial difficulties were also cited by the vendor in its decision not to exhibit at the annual meeting of the Society of Nuclear Medicine meeting in June (SCAN 6/25/97). Earlier, a deal to buy the PET assets of GE Medical Systems collapsed as a result of difficulties in securing funds for the acquisition (SCAN 4/30/97).
Positron's stock will now be traded on the OTC bulletin board. The company intends to reapply for listing as soon it completes its recapitalization and meets the minimum listing requirements, said Gary Wood, chairman.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.